OM:CLA B
OM:CLA BFood

Is Cloetta (OM:CLA B) Using CandyKing’s NYC Flagship to Quietly Reposition Its Global Brand Strategy?

CandyKing, part of Cloetta, announced on December 4, 2025 that it is opening a permanent Swedish candy store this week in New York City’s West Village, offering its full concept and exclusive products at 306 Bleecker Street. This U.S. flagship gives American consumers direct influence over the store’s evolving assortment, turning customer input into a core element of CandyKing’s offering. We’ll now examine how CandyKing’s New York flagship and U.S. expansion shape Cloetta’s investment...
OM:SOBI
OM:SOBIBiotechs

How Investors May Respond To Swedish Orphan Biovitrum (OM:SOBI) Aspaveli’s Positive EU Kidney-Disease Opinion

Swedish Orphan Biovitrum AB (Sobi) recently received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use recommending marketing authorisation of Aspaveli (pegcetacoplan) to treat adults and adolescents with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis across the European Union. If approved by the European Commission, Aspaveli would become the first authorised therapy for these rare, severe kidney diseases in patients 12...
OM:RUSTA
OM:RUSTAMultiline Retail

Assessing Rusta (OM:RUSTA) Valuation After Strong Q2, Nordic Online Rollout and Continued Store Expansion

Rusta (OM:RUSTA) just delivered a busy quarter, combining higher sales, stronger Q2 profits and fresh store openings with a full Nordic online rollout. This mix naturally puts the share in focus. See our latest analysis for Rusta. The market seems to be buying into that story, with the share price at SEK 82.05 after a punchy 1 month share price return of 25.84% and a 1 year total shareholder return of 16.50%. This suggests momentum is building as the earnings beat, new CEO announcement and...
OM:HM B
OM:HM BSpecialty Retail

Is H&M (OM:HM B) Overvalued After Its Recent Share Price Rebound? A Closer Look at the Valuation

H & M Hennes & Mauritz (OM:HM B) has been quietly rewarding patient shareholders, with the stock gaining about 22% over the past 3 months and roughly 20% year to date. See our latest analysis for H & M Hennes & Mauritz. At around SEK 178.65 per share, the 90 day share price return of about 22% and a three year total shareholder return above 80% suggest momentum is clearly building again as investors warm to H & M Hennes & Mauritz’s recovery story. If H & M’s rebound has you rethinking retail,...
OM:SAAB B
OM:SAAB BAerospace & Defense

Assessing Saab (OM:SAAB B) Valuation After Breakthrough Autonomous Aircraft Fuselage Milestone with Divergent Technologies

Saab (OM:SAAB B) just hit an interesting milestone with Divergent Technologies, delivering initial autonomous aircraft fuselages built using fully digital, additive manufacturing. For investors, this is less about near term revenue and more about long term capability. See our latest analysis for Saab. That milestone with Divergent lands after a busy spell for Saab, with fresh Spanish Army training contracts and another Lithuanian MSHORAD order. It comes on top of a powerful year to date share...
OM:BONEX
OM:BONEXBiotechs

Shifting CERAMENT V To FDA De Novo Review Might Change The Case For Investing In Bonesupport Holding (OM:BONEX)

BONESUPPORT has already shifted its U.S. regulatory route for CERAMENT V for bone infection from a 510(k) submission to the FDA’s De Novo pathway, extending the formal review period from 90 to 150 days while transferring substantial existing clinical and pharmacological documentation. This move suggests CERAMENT V could, if cleared, create a new product category in the U.S., echoing how CERAMENT G previously established a distinct regulatory class and potentially underscoring the uniqueness...
OM:SKA B
OM:SKA BConstruction

Is It Too Late To Consider Skanska After Contract Wins And Strong Multi Year Share Gains

Wondering if Skanska is still good value after its run over the last few years, or if most of the upside is already priced in? This breakdown will help you decide whether to keep watching or start acting. The stock has climbed about 2.0% over the last week, 3.3% year to date and 9.3% over the past year, while its 3 year gain of 60.9% and 5 year gain of 44.6% show that investors have already been rewarded for backing the story. Recent headlines have focused on Skanska winning new...